glp 1 agonist fda approval Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the Adverse Event Reporting System database | BMC Medicine Trends in the Development of

However, these studies found no significant improvements in a range of safety endpoints for cardiovascular diseases ( The Role of DPP-4 Inhibitors in Hypertension The first DPP-4 inhibitor, sitagliptin, was approved as an anti-hyperglycemic agent for T2DM in the United States of America in 2006

References 1 MalikVSWilletWCHuFB

placebo), SURPASS-2 (vs

Based on VigiBase, the World Health Organizations (WHO) adverse drug reaction database, intestinal obstructions are reported over 4.5 times more frequently with incretin-based drugs than with other diabetes medications [10]

Cotadutide produced greater improvement in liver histology, including reductions in steatosis, inflammation, and fibrosis relative to cohorts treated with liraglutide, in mice with experimental NASH after similar degrees of weight loss [42]